# Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors

**Authors:** Noboru Yamamoto, Takafumi Koyama, Jun Sato, Tatsuya Yoshida, Kazuki Sudo, Satoru Iwasa, Shunsuke Kondo, Kan Yonemori, Atsuko Kawasaki, Kyoko Satake, Shoyo Shibata, Toshio Shimizu

PMC · DOI: 10.1007/s00280-024-04645-9 · Cancer Chemotherapy and Pharmacology · 2024-03-31

## Full-text entities

- **Genes:** TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}
- **Diseases:** solid tumors (MESH:D009369)
- **Chemicals:** atezolizumab (MESH:C000594389), tiragolumab (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11420387/full.md

---
Source: https://tomesphere.com/paper/PMC11420387